CalciMedica Reports 2025 Financial Results and Provides Clinical Updates
Rhea-AI Summary
CalciMedica (Nasdaq: CALC) reported 2025 results and clinical updates on March 3, 2026. Cash and equivalents were $13.0M, expected to fund operations into Q4 2026. Net loss was $29.6M ($1.97/share) versus $13.7M ($1.22/share) in 2024.
Clinically, the Phase 2 KOURAGE AKI trial was discontinued following an IDMC recommendation related to a mortality imbalance; reviews found no drug-related toxicity. The company expects FDA discussions on KOURAGE in Q2 2026 and plans to finalize a pivotal acute pancreatitis program in 1H 2026. Preclinical CM5480 PAH data were published, with an IND anticipated in 2027.
Positive
- Phase 2b CARPO showed dose-dependent clinical benefits
- Published peer-reviewed CARPO and CM5480 manuscripts
- Constructive FDA engagement on pivotal acute pancreatitis program
- Cash runway into Q4 2026
Negative
- Net loss widened to $29.6M in 2025
- Other expenses increased by $16.9M versus 2024
- Phase 2 KOURAGE discontinued after IDMC mortality imbalance
Market Reaction – CALC
Following this news, CALC has gained 10.53%, reflecting a significant positive market reaction. Our momentum scanner has triggered 3 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $0.56. This price movement has added approximately $696K to the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
CALC is down 1.8% while key biotech peers like PSTV, TELO, TPST, VRCA and ACRV all show gains, pointing to stock-specific pressure rather than a sector move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 12 | Q3 2025 earnings | Positive | +4.0% | Q3 2025 results, solid cash runway and active KOURAGE and AP programs. |
| Aug 12 | Q2 2025 earnings | Negative | -10.1% | Wider net loss alongside ongoing KOURAGE enrollment and AP planning. |
| May 14 | Q1 2025 earnings | Positive | -0.9% | Strong cash plus credit facility and positive Auxora mortality analysis. |
| Mar 27 | 2024 results | Positive | +4.0% | Improved 2024 expenses, reduced net loss and continued KOURAGE enrollment. |
| Nov 13 | Q3 2024 earnings | Positive | -2.6% | Positive CARPO data and capital raise but stock traded lower afterward. |
Earnings-related releases have produced mixed reactions, with an average move of -1.11% and a blend of rallies and selloffs.
Across past earnings updates since Nov 2024, CalciMedica has repeatedly paired financials with Auxora and CM5480 progress and cash runway disclosures. Prior reports highlighted evolving AKI and acute pancreatitis trial plans, improving or shifting expense patterns, and periodic equity or debt financing. Market reactions have been inconsistent, with some positive moves on operational progress and other declines after widened losses. Today’s full-year 2025 results and clinical updates continue that pattern of combining pipeline milestones with liquidity visibility into 2026.
Historical Comparison
Past earnings updates for CALC have averaged a modest -1.11% move. Today’s pre-news decline of -1.8% fits the historical tendency for slightly negative reactions around financial reports.
Earnings releases have traced CalciMedica’s evolution from funding and advancing Auxora in AKI and acute pancreatitis toward broader CRAC inhibitor development, while managing recurring operating losses and extending cash runway.
Market Pulse Summary
The stock is surging +10.5% following this news. A strong positive reaction aligns with earnings releases that have occasionally been rewarded when paired with clear clinical progress and runway visibility. This update combines full-year 2025 results, a cash position of $13.0 million, guidance into Q4 2026, and supportive Auxora and CM5480 data. Investors would still need to weigh ongoing net losses of $29.6 million and prior volatility around KOURAGE-related developments when assessing durability.
Key Terms
acute kidney injury medical
acute hypoxemic respiratory failure medical
pulmonary arterial hypertension medical
investigational new drug regulatory
preclinical medical
AI-generated analysis. Not financial advice.
Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™
Design of pivotal program in acute pancreatitis (AP) expected in 1H 2026
JCI Insight publication of preclinical data demonstrates CM5480 as a potential differentiated therapy in pulmonary arterial hypertension (PAH); IND submission anticipated in 2027
"First and foremost, in acute kidney injury, we and our external advisors have reviewed the unblinded KOURAGE data and have found no evidence of a drug-related toxicity. We look forward to discussions with the FDA about potential future clinical studies in AKI. We are also advancing Auxora towards the pivotal program in acute pancreatitis following constructive FDA engagement and the peer-reviewed publication of our Phase 2b CARPO results. The Company plans to finalize the design for this program in the first half of this year," said Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica. "Concurrently, we continue to advance our second CRAC channel inhibitor, CM5480, in pulmonary arterial hypertension, following the recent publication of preclinical data which demonstrate its potential in cardiopulmonary disease."
Recent Program Highlights:
Acute Kidney Injury (AKI) with Acute Hypoxemic Respiratory Failure (AHRF) Program Update
- Phase 2 KOURAGE trial safety review: In January 2026, CalciMedica announced the discontinuation of the Phase 2 KOURAGE trial evaluating Auxora in patients with Stage 2 or Stage 3 AKI with associated AHRF. The decision followed a recommendation from the trial's Independent Data Monitoring Committee (IDMC) regarding a safety concern relating to a mortality imbalance that warranted reevaluation of the study design. The IDMC did not identify evidence of drug-related toxicity, and the Company's comprehensive review, performed in conjunction with external experts, reached the same conclusion. Imbalances in the patients' severity of disease at baseline may have contributed to the observed safety concern.
- Next steps in AKI: The Company plans to discuss the KOURAGE data and potential future development in AKI with the FDA in the second quarter of 2026. The trial remains ongoing for patient follow-up.
Acute Pancreatitis (AP) Program Update
- Positive FDA engagement on pivotal program in AP: CalciMedica continues constructive discussions with the
U.S. Food and Drug Administration (FDA) regarding the pivotal program for Auxora in AP and expects to finalize the program design in the first half of 2026. This would represent the firstU.S. pivotal program evaluating a therapeutic candidate for AP, an illness with approximately 300K hospitalizations annually in theU.S. - Phase 2b CARPO trial results published in eClinicalMedicine: In February 2026, a manuscript authored by CalciMedica and collaborators titled "Zegocractin for acute pancreatitis with systemic inflammatory response syndrome: a randomized, controlled, dose-ranging, phase 2b trial" was published in eClinicalMedicine, a journal in The Lancet Discovery Science suite. The publication details previously announced topline results from 214 patients enrolled in the Phase 2b CARPO trial of Auxora in AP with systemic inflammatory response syndrome (SIRS). In hyper-inflamed patients, Auxora demonstrated clinically meaningful, dose-dependent reductions in median time to solid food tolerance. Across the overall study population, Auxora demonstrated dose-dependent improvements in multiple clinically relevant endpoints, including reductions in organ failure, necrotizing pancreatitis, and time to medically indicated discharge. Notably, medium- and high-dose Auxora arms achieved a statistically significant
100% reduction in new-onset severe respiratory failure compared to placebo (p < 0.05), and the high-dose Auxora arm achieved a statistically significant stratified win ratio of 1.640 (p < 0.05), which represents a hierarchical composite of mortality, new-onset severe respiratory failure, new-onset necrotizing pancreatitis, and time to medically indicated discharge. Auxora was generally well tolerated, with a trend of decreasing treatment-emergent serious adverse event (TESAE) rates with increasing doses of drug. Additionally, there were no drug-related TESAEs or deaths in patients receiving the high dose of Auxora.
Pulmonary Arterial Hypertension (PAH) Program Update
- Publication in JCI Insight highlighting CM5480 in a pulmonary arterial hypertension (PAH) model: In November 2025, a manuscript authored by CalciMedica and collaborators titled "Combination of Orai1 Inhibitor CM5480 with Specific Therapy Mitigates Pulmonary Hypertension and Its Cardiac Dysfunction" was published in JCI Insight. The publication describes preclinical data supporting CalciMedica's proprietary CRAC channel inhibitor candidate, CM5480, as a potential first-in-class, differentiated therapy for the treatment of PAH. In an animal model of PAH, CM5480 restored or improved multiple disease-affected pathways and functions—including heart contraction and cardiac output, gene expression profiles, DNA repair, and metabolism. Treatment with CM5480 also significantly reduced right ventricular dysfunction (RVD) both as a monotherapy and in combination with existing PAH therapies.
- Preclinical activities to advance CM5480 in PAH underway: Ongoing studies are being conducted to further characterize CM5480's pharmacology, pharmacokinetics, and safety profile to support IND (investigational new drug)-enabling development in PAH. An IND submission is currently anticipated in 2027.
Financial Results for the Year Ended December 31, 2025:
Cash Position: Cash, cash equivalents, and short-term investments were
R&D Expenses: Research and development expenses were
G&A Expenses: General and administrative expenses were
Other Income (Expense): Other expenses were
Net Loss: Net loss was
About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in serious and life-threatening conditions with high unmet need. CalciMedica's lead product candidate Auxora™ has demonstrated positive clinical results in multiple completed efficacy clinical trials. The Company has reported data from a Phase 2b trial (CARPO; NCT04681066) evaluating Auxora in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS), as well as from a Phase 2 trial (CARDEA; NCT04345614) in patients with severe COVID-19 pneumonia. The Company initiated a Phase 2 trial (KOURAGE; NCT06374797) evaluating Auxora in patients with acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF); in January 2026, the trial was discontinued following a recommendation from the Independent Data Monitoring Committee, and the Company plans to discuss potential future development in AKI with the FDA. In addition, CalciMedica is advancing CM5480 as a potential therapy for pulmonary arterial hypertension (PAH), supported by preclinical data demonstrating effects on pulmonary vascular remodeling and right ventricular function. For more information, please visit www.calcimedica.com.
Forward-Looking Statements
This communication contains forward-looking statements which include, but are not limited to, CalciMedica's expected cash runway; CalciMedica's planned and ongoing clinical trials and the timing, design, and the expected timing for updates; statements regarding the anticipated timing of filing an IND; statements regarding the safety and efficacy of its product candidates; statements regarding FDA's positive engagement on a pivotal program for Auxora in AP and a final pivotal program design in the first half of 2026; statements regarding the analysis of the unblinded KOURAGE dataset, including timing of discussions with the FDA and whether such analysis will inform future trial parameters; and the potential of CalciMedica's proprietary technology to provide therapeutic benefits in PAH and other acute and chronic inflammatory and immunologic diseases such as AKI, AP, and AIPT. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. CalciMedica's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances, including but not limited to risks and uncertainties related to: the impact of fluctuations in global financial markets on CalciMedica's business and the actions it may take in response thereto; CalciMedica's ability to execute its plans and strategies; the ability to obtain and maintain regulatory approval for Auxora; results from clinical trials or preclinical studies may not be indicative of results that may be observed in the future; potential safety and other complications from Auxora; the scope, progress and expansion of developing and commercializing Auxora; the size and growth of the market therefor and the rate and degree of market acceptance thereof; economic, business, competitive, and/or regulatory factors affecting the business of CalciMedica generally; CalciMedica's ability to protect its intellectual property position; the impact of government laws and regulations; and CalciMedica's financial position and need for additional capital. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption "Risk Factors" in CalciMedica's Annual Report on Form 10-K for the year ended December 31, 2025, being filed with the Securities and Exchange Commission (SEC) later today, and elsewhere in CalciMedica's subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at www.sec.gov. These documents can be accessed on CalciMedica's web page at ir.calcimedica.com/financials-filings/sec-filings. The forward-looking statements contained herein are made as of the date hereof, and CalciMedica undertakes no obligation to update them after this date, except as required by law.
Contact Information
Kevin Murphy
calcimedica@argotpartners.com (212) 600-1902
CALCIMEDICA, INC. Consolidated Balance Sheets (in thousands, except par value and share amounts) (Audited) | ||||||||
December 31, | December 31, | |||||||
Assets | ||||||||
Current assets | ||||||||
Cash and cash equivalents | $ | 11,520 | $ | 7,935 | ||||
Short-term investments | 1,496 | 10,734 | ||||||
Prepaid clinical trial expenses | 201 | 748 | ||||||
Other prepaid expenses and current assets | 259 | 248 | ||||||
Assets held for sale | 54 | — | ||||||
Total current assets | 13,530 | 19,665 | ||||||
Property and equipment, net | 50 | 119 | ||||||
Other assets | 11 | 10 | ||||||
Total assets | $ | 13,591 | $ | 19,794 | ||||
Liabilities and Stockholders' Equity (Deficit) | ||||||||
Current liabilities | ||||||||
Accounts payable | $ | 1,161 | $ | 1,998 | ||||
Accrued clinical trial costs | 1,081 | 820 | ||||||
Accrued expenses | 290 | 866 | ||||||
Current portion, promissory note | 1,250 | — | ||||||
Total current liabilities | 3,782 | 3,684 | ||||||
Long-term liabilities | ||||||||
Promissory note | 8,450 | — | ||||||
Warrant liability | 8,000 | 1,700 | ||||||
Total liabilities | 20,232 | 5,384 | ||||||
Commitments and contingencies (Note 8) | ||||||||
Stockholders' equity (deficit) | ||||||||
Preferred stock, | — | — | ||||||
Common stock, | 4 | 4 | ||||||
Additional paid-in capital | 182,681 | 174,166 | ||||||
Accumulated deficit | (189,326) | (159,764) | ||||||
Accumulated other comprehensive income | — | 4 | ||||||
Total stockholders' equity (deficit) | (6,641) | 14,410 | ||||||
Total liabilities and stockholders' equity (deficit) | $ | 13,591 | $ | 19,794 | ||||
CALCIMEDICA, INC. Consolidated Statements of Operations (in thousands, except share and per share amounts) (Audited) | ||||||||
Year Ended December 31, | ||||||||
2025 | 2024 | |||||||
Operating expenses: | ||||||||
Research and development | $ | 15,234 | $ | 14,478 | ||||
General and administrative | 7,887 | 9,726 | ||||||
Total operating expenses | 23,121 | 24,204 | ||||||
Loss from operations | (23,121) | (24,204) | ||||||
Other income (expense): | ||||||||
Change in fair value of financial instruments | (6,000) | 9,490 | ||||||
Interest expense | (1,422) | — | ||||||
Interest income | 713 | 1,014 | ||||||
Other income | 268 | — | ||||||
Total other income (expense) | (6,441) | 10,504 | ||||||
Net loss | $ | (29,562) | $ | (13,700) | ||||
Net loss per share - basic and diluted | $ | (1.97) | $ | (1.22) | ||||
Weighted-average number of shares outstanding used in | 15,011,321 | 11,245,915 | ||||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-reports-2025-financial-results-and-provides-clinical-updates-302701714.html
SOURCE CalciMedica, Inc.
FAQ
Why did CalciMedica (CALC) discontinue the Phase 2 KOURAGE AKI trial in January 2026?
What are the next regulatory steps for CalciMedica (CALC) after the KOURAGE discontinuation?
What did CalciMedica report about Auxora results in the Phase 2b CARPO trial (published Feb 2026)?
When will CalciMedica finalize the pivotal acute pancreatitis (AP) program design for Auxora (CALC)?
What is the status of CalciMedica's CM5480 program for pulmonary arterial hypertension (CALC)?
How long is CalciMedica's cash runway based on the March 3, 2026 report (CALC)?
